Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.

Castro M, Rabe KF, Corren J, Pavord ID, Katelaris CH, Tohda Y, Zhang B, Rice MS, Maroni J, Rowe P, Pirozzi G, Amin N, Ruddy M, Akinlade B, Graham NMH, Teper A.

ERJ Open Res. 2020 Jan 27;6(1). pii: 00204-2019. doi: 10.1183/23120541.00204-2019. eCollection 2020 Jan.

2.

Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M, Ardeleanu M, Teper A, Akinlade B, Gadkari A, Eckert L, Kamal MA, Ruddy M, Graham NMH, Pirozzi G, Stahl N, DiCioccio AT, Bansal A.

Br J Dermatol. 2020 Jan;182(1):85-96. doi: 10.1111/bjd.18476. Epub 2019 Oct 8.

3.

Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis.

Lubovich S, Zaragoza S, Rodríguez V, Buendía J, Camargo Vargas B, Alchundia Moreira J, Galanternik L, Ratto P, Teper A.

Arch Argent Pediatr. 2019 Oct 1;117(5):e466-e472. doi: 10.5546/aap.2019.eng.e466. English, Spanish.

4.

Course of lung function in children with cystic fibrosis in their first 3 years of life.

Balinotti JE, Chang DV, Lubovich S, Rodríguez V, Zaragoza S, Escobar N, Kofman C, Pérez GL, Ardiles V, Teper A.

Arch Argent Pediatr. 2019 Oct 1;117(5):323-329. doi: 10.5546/aap.2019.eng.323. English, Spanish.

5.

Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.

Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu Y, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A.

J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526. doi: 10.1016/j.jaip.2019.08.050. Epub 2019 Sep 12.

6.

Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.

Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan AH, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent LP, Teper A.

J Allergy Clin Immunol Pract. 2020 Feb;8(2):527-539.e9. doi: 10.1016/j.jaip.2019.07.016. Epub 2019 Jul 24.

7.

Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history.

Corren J, Castro M, Ford LB, Bernstein JA, Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham NMH, Khan A, Eckert L, Teper A.

Ann Allergy Asthma Immunol. 2019 Aug;123(2):222-224.e1. doi: 10.1016/j.anai.2019.04.028. Epub 2019 May 8. No abstract available.

8.

Conjunctivitis in dupilumab clinical trials.

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A.

Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7.

9.

Exhaled nitric oxide predicts loss of asthma control in children after inhaled corticosteroids withdrawal.

Chang DV, Teper A, Balinotti J, Castro Simonelli C, Garcia-Bournissen F, Kofman C.

Pediatr Pulmonol. 2019 May;54(5):537-543. doi: 10.1002/ppul.24268. Epub 2019 Jan 27.

PMID:
30688035
10.

Clinical, functional, and radiological outcome in children with pleural empyema.

Maffey A, Colom A, Venialgo C, Acastello E, Garrido P, Cozzani H, Eguiguren C, Teper A.

Pediatr Pulmonol. 2019 May;54(5):525-530. doi: 10.1002/ppul.24255. Epub 2019 Jan 23.

PMID:
30675767
11.

Post-infectious bronchiolitis obliterans.

Colom AJ, Teper AM.

Pediatr Pulmonol. 2019 Feb;54(2):212-219. doi: 10.1002/ppul.24221. Epub 2018 Dec 12. Review.

PMID:
30548423
12.

Usefulness of Nonvalved Spacers for Administration of Inhaled Steroids in Young Children with Recurrent Wheezing and Risk Factors for Asthma.

Kofman C, Teper A.

Can Respir J. 2018 Sep 3;2018:3095647. doi: 10.1155/2018/3095647. eCollection 2018.

13.

Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma.

Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbé A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L.

Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2. doi: 10.1016/j.anai.2018.08.005. Epub 2018 Aug 21.

14.

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21.

15.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

16.

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A.

Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3.

17.

Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.

Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A.

J Allergy Clin Immunol. 2018 Jul;142(1):171-177.e1. doi: 10.1016/j.jaci.2017.11.051. Epub 2018 Jan 31.

18.

Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus in Cystic Fibrosis Patients from Argentina.

Pena Amaya P, Haim MS, Fernández S, Di Gregorio S, Teper A, Vázquez M, Lubovich S, Galanternik L, Mollerach M.

Microb Drug Resist. 2018 Jun;24(5):613-620. doi: 10.1089/mdr.2017.0162. Epub 2017 Nov 29.

PMID:
29185854
19.

Severe asthma and asthma-chronic obstructive pulmonary disease syndrome - Authors' reply.

Wenzel SE, Jayawardena S, Graham NM, Pirozzi G, Teper A.

Lancet. 2016 Dec 3;388(10061):2742. doi: 10.1016/S0140-6736(16)31720-2. Epub 2016 Dec 2. No abstract available.

PMID:
27924776
20.

Official American Thoracic Society Clinical Practice Guidelines: Diagnostic Evaluation of Infants with Recurrent or Persistent Wheezing.

Ren CL, Esther CR Jr, Debley JS, Sockrider M, Yilmaz O, Amin N, Bazzy-Asaad A, Davis SD, Durand M, Ewig JM, Yuksel H, Lombardi E, Noah TL, Radford P, Ranganathan S, Teper A, Weinberger M, Brozek J, Wilson KC; ATS Ad Hoc Committee on Infants with Recurrent or Persistent Wheezing.

Am J Respir Crit Care Med. 2016 Aug 1;194(3):356-73. doi: 10.1164/rccm.201604-0694ST.

PMID:
27479061
21.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A.

Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27.

PMID:
27130691
22.

[Pleuropulmonary blastoma, case report].

Bosch JJ, Medín M, Garrido P, Martínez J, Teper A.

Arch Argent Pediatr. 2016 Feb;114(1):e25-8. doi: 10.5546/aap.2016.e25. Spanish.

23.

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M.

Lancet. 2016 Jan 2;387(10013):40-52. doi: 10.1016/S0140-6736(15)00388-8. Epub 2015 Oct 8.

PMID:
26454361
24.

Opioid Use Trajectories, Injection Drug Use, and Hepatitis C Virus Risk Among Young Adult Immigrants from the Former Soviet Union Living in New York City.

Guarino H, Marsch LA, Deren S, Straussner SL, Teper A.

J Addict Dis. 2015;34(2-3):162-77. doi: 10.1080/10550887.2015.1059711.

25.

Authors' response: Long-term lung function in postinfectious bronchiolitis obliterans.

Colom A, Maffey A, Garcia Bournissen F, Teper A.

Thorax. 2015 Aug;70(8):793. doi: 10.1136/thoraxjnl-2015-207112. Epub 2015 May 7. No abstract available.

PMID:
25953478
26.

Pulmonary function of a paediatric cohort of patients with postinfectious bronchiolitis obliterans. A long term follow-up.

Colom AJ, Maffey A, Garcia Bournissen F, Teper A.

Thorax. 2015 Feb;70(2):169-74. doi: 10.1136/thoraxjnl-2014-205328. Epub 2014 Nov 11.

PMID:
25388479
27.

High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users.

Frank D, Mateu-Gelabert P, Guarino H, Bennett A, Wendel T, Jessell L, Teper A.

Int J Drug Policy. 2015 Jan;26(1):84-91. doi: 10.1016/j.drugpo.2014.07.013. Epub 2014 Jul 31.

28.

Injection and sexual HIV/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City.

Mateu-Gelabert P, Guarino H, Jessell L, Teper A.

J Subst Abuse Treat. 2015 Jan;48(1):13-20. doi: 10.1016/j.jsat.2014.07.002. Epub 2014 Jul 11.

29.

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).

Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL, Singh J, Spuls P, Thomas KS, Admani S, Aoki V, Ardeleanu M, Barbarot S, Berger T, Bergman JN, Block J, Borok N, Burton T, Chamlin SL, Deckert S, DeKlotz CC, Graff LB, Hanifin JM, Hebert AA, Humphreys R, Katoh N, Kisa RM, Margolis DJ, Merhand S, Minnillo R, Mizutani H, Nankervis H, Ohya Y, Rodgers P, Schram ME, Stalder JF, Svensson A, Takaoka R, Teper A, Tom WL, von Kobyletzki L, Weisshaar E, Zelt S, Williams HC.

Br J Dermatol. 2014 Dec;171(6):1318-25. doi: 10.1111/bjd.13237. Epub 2014 Nov 14.

30.

Effects of mometasone, fluticasone, and montelukast on bone mineral density in adults with asthma.

Maspero J, Backer V, Yao R, Staudinger H, Teper A.

J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):649-55.e1. doi: 10.1016/j.jaip.2013.07.011. Epub 2013 Oct 8.

PMID:
24565713
31.

Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma.

Berger WE, Bensch GW, Weinstein SF, Skoner DP, Prenner BM, Shekar T, Nolte H, Teper AA.

Pediatr Pulmonol. 2014 May;49(5):441-50. doi: 10.1002/ppul.22850. Epub 2013 Sep 9.

PMID:
24019197
32.

Association between the Asthma Predictive Index and levels of exhaled nitric oxide in infants and toddlers with recurrent wheezing.

Balinotti JE, Colom A, Kofman C, Teper A.

Arch Argent Pediatr. 2013 Jun;111(3):191-5. doi: 10.1590/S0325-00752013000300003. English, Spanish.

33.

Swallowing and respiratory distress in hospitalized patients with bronchiolitis.

Maffey A, Moviglia T, Mirabello C, Blumenthal L, Gentile L, Niremberg M, Gilligan G, Teper A.

Dysphagia. 2013 Dec;28(4):582-7. doi: 10.1007/s00455-013-9470-0. Epub 2013 May 21.

PMID:
23689810
34.

Relieving nasal congestion in children with seasonal and perennial allergic rhinitis: efficacy and safety studies of mometasone furoate nasal spray.

Meltzer EO, Baena-Cagnani CE, Gates D, Teper A.

World Allergy Organ J. 2013 Mar 4;6(1):5. doi: 10.1186/1939-4551-6-5.

35.

Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis.

Meltzer EO, Bernstein DI, Prenner BM, Berger WE, Shekar T, Teper AA.

Am J Rhinol Allergy. 2013 Mar-Apr;27(2):102-8. doi: 10.2500/ajra.2013.27.3864.

PMID:
23562197
36.

Safety of mometasone furoate nasal spray in the treatment of nasal polyps in children.

Chur V, Small CB, Stryszak P, Teper A.

Pediatr Allergy Immunol. 2013 Feb;24(1):33-8. doi: 10.1111/pai.12032.

PMID:
23331528
37.

[Poorly controlled asthma: diagnosis and therapeutics in children and adolescents].

Neffen H, Vidaurreta S, Balanzat A, De Gennaro MS, Giubergia V, Maspero JF, Saranz RJ, Teper AM.

Medicina (B Aires). 2012;72(5):403-13. Review. Spanish.

38.

[Pulmonary hemorrhage associated with celiac disease].

Testa ME, Maffey A, Colom A, Agüero L, Rogé I, Andrewartha MS, Teper A.

Arch Argent Pediatr. 2012 Aug;110(4):e72-6. doi: 10.1590/S0325-00752012000400016. Spanish.

39.

Effects of intranasal mometasone furoate on itchy ear and palate in patients with seasonal allergic rhinitis.

Bernstein DI, Teper A, Gopalan G, Gates D.

Ann Allergy Asthma Immunol. 2012 May;108(5):359-62. doi: 10.1016/j.anai.2012.02.023. Epub 2012 Mar 23.

PMID:
22541408
40.

Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.

Skoner DP, Meltzer EO, Milgrom H, Stryszak P, Teper A, Staudinger H.

J Asthma. 2011 Oct;48(8):848-59. doi: 10.3109/02770903.2011.604883. Epub 2011 Aug 22.

PMID:
21854342
41.

Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis.

Meltzer EO, Shekar T, Teper AA.

Allergy Asthma Proc. 2011 Mar-Apr;32(2):159-67. doi: 10.2500/aap.2011.32.3424.

PMID:
21439168
42.

Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial.

Teper A, Jaques A, Charlton B.

J Cyst Fibros. 2011 Jan;10(1):1-8. doi: 10.1016/j.jcf.2010.08.020.

43.

Viruses and atypical bacteria associated with asthma exacerbations in hospitalized children.

Maffey AF, Barrero PR, Venialgo C, Fernández F, Fuse VA, Saia M, Villalba A, Fermepin MR, Teper AM, Mistchenko AS.

Pediatr Pulmonol. 2010 Jun;45(6):619-25. doi: 10.1002/ppul.21236.

PMID:
20503289
44.

Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis.

Prenner BM, Lanier BQ, Bernstein DI, Shekar T, Teper A.

J Allergy Clin Immunol. 2010 Jun;125(6):1247-1253.e5. doi: 10.1016/j.jaci.2010.03.004.

PMID:
20434199
45.

Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents.

Anolik R, Pearlman D, Teper A, Gates D.

Allergy Rhinol (Providence). 2010 Jan 1;1(1):5. doi: 10.2500/aap.2009.30.3238. No abstract available.

PMID:
28569225
46.

Clinical prediction rule to diagnose post-infectious bronchiolitis obliterans in children.

Colom AJ, Teper AM.

Pediatr Pulmonol. 2009 Nov;44(11):1065-9. doi: 10.1002/ppul.21080.

PMID:
19830721
47.

Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents.

Anolik R, Pearlman D, Teper A, Gates D.

Allergy Asthma Proc. 2009 Jul-Aug;30(4):406-12. doi: 10.2500/aap.2009.30.3238. Epub 2009 May 22.

PMID:
19467175
48.

[Postinfectious bronchiolitis obliterans].

Colom AJ, Teper AM.

Arch Argent Pediatr. 2009 Apr;107(2):160-7. doi: 10.1590/S0325-00752009000200011. Review. Spanish.

49.

Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis.

Ratner PH, Meltzer EO, Teper A.

Int J Pediatr Otorhinolaryngol. 2009 May;73(5):651-7. doi: 10.1016/j.ijporl.2008.12.025. Epub 2009 Feb 23.

PMID:
19233485
50.

[New respiratory viruses in children 2 months to 3 years old with recurrent wheeze].

Maffey AF, Venialgo CM, Barrero PR, Fuse VA, Márques Mde L, Saia M, Villalba A, Teper AM, Mistchenko AS.

Arch Argent Pediatr. 2008 Aug;106(4):302-9. doi: 10.1590/S0325-00752008000400005. Spanish.

Supplemental Content

Support Center